A Phase 1/2a, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients With Advanced Solid Malignancies

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

开始日期2021-12-29

申办/合作机构

23andMe, Inc.

100 项与 23ME-00610 相关的临床结果

登录后查看更多信息

100 项与 23ME-00610 相关的转化医学

登录后查看更多信息

100 项与 23ME-00610 相关的专利（医药）

登录后查看更多信息

项与 23ME-00610 相关的文献（医药）

2024-12-31·mAbs

CD200R1 immune checkpoint blockade by the first-in-human anti-CD200R1 antibody 23ME-00610: molecular mechanism and engineering of a surrogate antibody

Article

作者: Huang, Yao-Ming ; Daruwalla, Anahita ; Heiler, Alexander J. ; Ganichkin, Oleg ; Chung, Ben ; Fenaux, Jill ; Budiardjo, S. Jimmy ; Larrabee, Lance ; Fuh, Germaine ; Melero, Cristina

Human CD200R1 (hCD200R1), an immune inhibitory receptor expressed predominantly on T cells and myeloid cells, was identified as a promising immuno-oncology target by the 23andMe database. Blockade of CD200R1-dependent signaling enhances T cell-mediated antitumor activity in vitro and in vivo. 23ME-00610 is a potential first-in-class, humanized IgG1 investigational antibody that binds hCD200R1 with high affinity. We have previously shown that 23ME-00610 inhibits the hCD200R1 immune checkpoint function. Herein, we dissect the molecular mechanism of 23ME-00610 blockade of hCD200R1 by solving the crystal structure of 23ME-00610 Fab in complex with hCD200R1 and performing mutational studies, which show 23ME-00610 blocks the interaction between hCD200 and hCD200R1 through steric hindrance. However, 23ME-00610 does not bind CD200R1 of preclinical species such as cynomolgus monkey MfCD200R1. To enable preclinical toxicology studies of CD200R1 blockade in a pharmacologically relevant non-clinical species, we engineered a surrogate antibody with high affinity toward MfCD200R1. We used phage display libraries of 23ME-00610 variants with individual CDR residues randomized to all 20 amino acids, from which we identified mutations that switched on MfCD200R1 binding. Structural analysis suggests how the surrogate, named 23ME-00611, acquires the ortholog binding ability at the equivalent epitope of 23ME-00610. This engineering approach does not require a priori knowledge of structural and functional mapping of antibody-antigen interaction and thus is generally applicable for therapeutic antibody development when desired ortholog binding is lacking. These findings provide foundational insights as 23ME-00610 advances in clinical studies to gain understanding of the hCD200R1 immune checkpoint as a target in immuno-oncology.

2024-02-01·Journal of peptide science : an official publication of the European Peptide Society

The development and optimisation of an HPLC‐based in vitro serum stability assay for a calcitonin gene‐related peptide receptor antagonist peptide

Article

作者: Hutcheon, Gillian A. ; Coxon, Christopher R. ; Kendall, David A. ; Schofield, Adam ; D'Aloisio, Vera

Evaluation of the stability of peptide drug candidates in biological fluids, such as blood serum, is of high importance during the lead optimisation phase. Here, we describe the optimisation and validation of a method for the evaluation of the stability of a lead calcitonin gene‐related peptide antagonist peptide (P006) in blood serum. After initially determining appropriate peptide and human serum concentrations and selection of the quenching reagent, the HPLC method optimisation used two experimental designs, Plackett–Burman design and Taguchi design. The analytical method was validated as complying with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. The optimised method allowed the successful resolution of the parent peptide from its metabolites using RP‐HPLC and identification of the major metabolites of P006 by mass spectrometry. This paradigm may be widely adopted as a robust early‐stage platform for screening peptide stability to rule out candidates with low in vitro stability, which would likely translate into poor in vivo pharmacokinetics.

2023-12-31·Oncoimmunology

23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function

Article

作者: Poggio, Mauro ; Zhou, Aileen ; Palumbo, Tiziana ; Lowe, Earth Light ; Chung, Wei-Jen ; Lee, Clarissa C ; Fenaux, Jill ; Melero, Cristina ; Yi, Zuoan ; Huang, Yao-Ming ; Schmidt, Maike ; Fang, Xin ; Glatt, Dylan ; Chen, Alice ; Lay, Cecilia ; Bonnans, Caroline ; Majeed, Sophia R

Immune checkpoint inhibition (ICI) has revolutionized cancer treatment; however, only a subset of patients benefit long term. Therefore, methods for identification of novel checkpoint targets and development of therapeutic interventions against them remain a critical challenge. Analysis of human genetics has the potential to inform more successful drug target discovery. We used genome-wide association studies of the 23andMe genetic and health survey database to identify an immuno-oncology signature in which genetic variants are associated with opposing effects on risk for cancer and immune diseases. This signature identified multiple pathway genes mapping to the immune checkpoint comprising CD200, its receptor CD200R1, and the downstream adapter protein DOK2. We confirmed that CD200R1 is elevated on tumor-infiltrating immune cells isolated from cancer patients compared to the matching peripheral blood mononuclear cells. We developed a humanized, effectorless IgG1 antibody (23ME-00610) that bound human CD200R1 with high affinity (K_D <0.1 nM), blocked CD200 binding, and inhibited recruitment of DOK2. 23ME-00610 induced T-cell cytokine production and enhanced T cell-mediated tumor cell killing in vitro. Blockade of the CD200:CD200R1 immune checkpoint inhibited tumor growth and engaged immune activation pathways in an S91 tumor cell model of melanoma in mice.

项与 23ME-00610 相关的新闻（医药）

2024-09-17

·EndPoints

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

BARCELONA — A month after gutting its internal drug discovery group , 23andMe is trudging along with the experimental medicines it’s already brought into the clinic. 23andMe has struggled with its dual identity as a human genetics company and drug R&D outfit. It’s now getting into the GLP-1 arena , and its CEO Anne Wojcicki wants to take the company private , though last week she said she’d be open to takeover approaches from third parties. Between presentations at the American Society of Clinical Oncology in June and this weekend’s European Society for Medical Oncology, 23andMe essentially turned the page on its drug discovery work, letting go of about 30 employees. “There are assets within that discovery program that we’re continuing to hope to find partners and others to bring that forward,” 23andMe’s head of therapeutics development Jennifer Low told Endpoints News on the sidelines of ESMO on Sunday. The discovery team had honed in on immunology and inflammation last year. Despite the take-private talks and dwindling value of the company, 23andMe isn’t planning to fully exit drug development. “Anne remains dedicated to our programs and so I can’t comment on the business side of it, but it’s something that she still feels very passionately about,” Low said. Now, the future of 23andMe’s therapeutics arm largely rests on its two clinical-stage medicines, the Phase 2a 23ME-00610, and 23ME-01473, which just entered Phase 1 in March. If the two experimental drugs succeed in early testing, though, 23andMe will have to find a partner to carry them into more advanced trials, its leaders have said . “We’re really happy to be here. We’re a relatively small team, and to get this much — we got five posters here — it is pretty exceptional for the small company that we are,” Low said. One of the posters won “best poster” on Sunday, Low said. Patients in a clinical trial of 23ME-00610 used the same genetics kit that many consumers have used. “So everybody did the same spit in the tube that we do with our commercial kit,” Low said. It helps researchers decipher the influence that genetics can have on adverse events and efficacy. “We’re starting to see hints of that, that certain known polygenic predictors of autoimmune susceptibility also predict efficacy in our Phase 1/2 population,” Low said. “It’s really remarkable because you usually don’t see these sorts of trends this early in development.” Meanwhile, the company presented mouse model data on 23ME-01473, a ULBP6-targeting antibody. “It not only targets ULBP6 very potently, it also has other signaling enhancements in order to better activate NK cells and T cells to attack tumors,” Low said. She noted it could have better potential than other NK modalities, which “have been disappointing in their efficacy” because of short half-lives and other factors.

ASCO会议临床2期

2024-09-15

·GlobeNewswire-Health Care

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit, suggesting potential value as patient selection biomarkers Greater response in “cold” tumors suggests opportunity in patients unable to benefit from PD-1/PD-L1 checkpoint inhibitors SUNNYVALE, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from its Phase 1/2a clinical trial covering two new patient cohorts from 23ME-00610 (’610), a first-in-class anti-CD200R1 antibody, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, September 13-17. 23andMe Therapeutics presented posters summarizing results for 10 patients with clear-cell renal-cell carcinoma (ccRCC) and for 13 patients with tumor mutational burden-high (TMB-H) or microsatellite instability-high (MSI-H) cancers. A third poster summarized data from 118 participants across the Phase 1/2a trial to evaluate high tumor expression of CD200 as a potential predictive biomarker of clinical benefit. These presentations supplement data for cohorts with neuroendocrine and ovarian cancer presented earlier this year at the 2024 American Society of Clinical Oncology Meeting. (The 23andMe ESMO posters are available on the 23andMe Therapeutics and Investor websites). “We continue to be encouraged by evidence for therapeutic potential, in the form of multiple patients with durable clinical benefit from ’610,” said Jennifer Low, M.D., Ph.D., Head of Therapeutics Development, 23andMe. “Furthermore, the emergence of CD200 expression as a candidate biomarker has the potential to give us a powerful tool for patient selection. The progress we have made to date suggests that interrupting the CD200/CD200R1 pathway has great potential to reverse immune suppression in the tumor microenvironment and to help cancer patients who have progressed after multiple lines of treatment, including existing checkpoint inhibitors.” 23ME-00610 is a first-in-class IgG1 antibody designed to reverse immunosuppression by inhibiting binding of CD200R1 on immune cells with CD200 on tumor cells. In preclinical studies, this mechanism leads to restoration of T cell activity and killing of CD200-expressing tumor cells. The CD200R1 axis was recognized as a potentially significant checkpoint inhibition pathway through the identification of pleiotropic causal variants with opposing effect on risk for cancer and immune diseases, referred to by 23andMe Therapeutics as an immuno-oncology signature. Key Takeaways: Confirmed partial response (38% decrease in measured tumor burden) in a patient with refractory ccRCC (>11 cycles at data cut-off).23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed every three weeks.Higher tumor expression of CD200 may be associated with clinical benefit in some patient groups treated with 23ME-00610, warranting further exploration of this biomarker.In addition to CD200 expression, histology data suggest that immunosuppressed (“cold”) tumors may be more likely to exhibit disease control with 23ME-00610. Biopsied patients that had tumor shrinkage or prolonged stable disease with 23ME-00610 treatment tended to be less inflamed at baseline and have lower levels of immunosuppressive (M2) macrophages.Emerging data demonstrate the potential interaction of a tumor biomarker with host genetics, leveraging 23andMe developed polygenic risk scores. Further details - ccRCC cohort Between June 5 and December 12, 2023, ten adult patients with advanced ccRCC who received a median of four prior treatment lines (range: 2-7) were enrolled and received a median of three cycles (range: 2-12) of 23ME-00610, with three patients remaining on study at the July 1, 2024 data cutoff.In a 61 year old male, a confirmed partial response and ongoing treatment duration > 32 weeks for a treatment of refractory kidney cancer with high CD200 tumor expression was observed.The safety and tolerability profile remains acceptable and promising for potential anti-cancer combinations in ccRCC patients. No treatment-emergent adverse events (TEAEs) leading to 23ME-00610 dose interruption or discontinuation were reported.Related treatment-emergent adverse events (TEAEs) occurred in three patients (30%); all were G1/G2, were reported once each (10%), and included dry mouth, nausea, constipation and vomiting. Preliminary baseline tumor data may suggest that highly vascularized tumors with high CD200 associates with beneﬁt from 23ME-00610 treatment. Further details – TMB-H/MSI-H cohort Between June 20, 2023 and April, 2024, 13 adult patients with locally advanced or metastatic TMB-H (N=11; 84.6%) and/or MSI-H (N=5; 38.5%) solid cancers who received a median of five prior treatments (range 3-11; prior immunotherapy in 84.6%) were enrolled and received a median of three cycles of 23ME-00610 (range 1-11), and 1 patient remaining on study at the July 1, 2024 data cutoff. Further details – CD200 biomarker Between January 2022 and April 2024, 118 adult patients with locally advanced and metastatic solid tumors were enrolled in the Phase 1/2a clinical trial for 23ME-00610. Archival tissue and genotyping was requested from all patients, and some subsets of patients received baseline and on-treatment biopsies.Higher tumor cell expression of CD200 associates with 23ME-00610 in some patients, and is further augmented if combined with genetic based host immune set point readouts (e.g. autoimmune hypothyroidism polygenic risk score), warranting further exploration of this and other biomarkers for potential future patient selection.Neuroendocrine tumors that had tumor shrinkage or prolonged stable disease tended to be less inflamed at baseline, though potentially more permissive to immune activation due to lower macrophage to lymphocyte ratio.Analysis of pre- and on-treatment tumor samples showed an increase in T and NK cell markers and an increase in interferon inducible genes with 23ME-00610 treatment suggesting pharmacodynamic immune modulation. About 23ME-0061023ME-00610 is a monoclonal antibody that binds to CD200R1 to prevent the interaction of CD200R1 with CD200. Using the world’s largest proprietary database of health and genetic information, 23andMe identified genetic variants of CD200R1, CD200, and DOK2, the downstream signaling protein, associated with higher risks of immune disease and lower risks of cancer, pinpointing CD200R1 as a promising immuno-oncology target.Additional preclinical data validated the CD200-CD200R1 pathway as an immune checkpoint, and potential target for reversing immune tolerance in cancer as a monotherapy, or in combination with other therapies. Clinical data from the dose escalation cohort of patients with advanced solid tumors has shown 23ME-00610 has favorable pharmacokinetics (PK) for dosing once every three weeks, expected on-target pharmacologic activity, and a promising safety and tolerability profile. About 23andMe23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit https://therapeutics.23andme.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise. Contacts:Investor Relations Contact: investors@23andMe.comMedia Contact: press@23andMe.com

临床结果ASCO会议免疫疗法临床2期

2024-09-03

·GlobeNewswire-Health Care

23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024

Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with 23ME-00610 efficacy to be presented Preclinical murine data on 23ME-01473 to be presented; Phase 1/2a dose escalation study ongoing SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that it will display three poster presentations on 23ME-00610, a first-in-class anti-CD200R1 antibody, and two on 23ME-01473, an anti-ULBP6 monoclonal antibody, at the European Society for Medical Oncology (ESMO) Congress 2024, taking place September 13 – September 17 in Barcelona, Spain. 23andMe will present additional preliminary clinical data, including efficacy data, for the clear-cell renal-cell carcinoma and high tumor microsatellite instability and/or high tumor mutational burden patient cohorts in the Phase 2a portion of its ongoing Phase 1/2a clinical trial evaluating 23ME-00610, as well as share further analyses on an exploratory tissue-based biomarker, CD200. In Phase 2 data presented at the American Society of Clinical Oncology (ASCO) in June, monotherapy 23ME-00610 demonstrated a continued acceptable safety and tolerability profile and preliminary evidence of clinical benefit in neuroendocrine and ovarian cohorts, including one confirmed partial response in a patient with well-differentiated pancreatic neuroendocrine cancer. Additionally, data showed early evidence pointing to CD200 as a potential tissue-based biomarker. The Company will present preclinical data on the 23ME-01473 program, as well as a trials in progress presentation on the Phase 1 clinical trial that began in March 2024. 23ME-01473 targets soluble ULBP6, which is released by cancer cells to promote an immunosuppressive tumor microenvironment. It is also Fc-effector enhanced to provide an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells. 23andMe scientists discovered the targets for 23ME-00610 and 23ME-01473 through the Company’s proprietary database of human genetic and health information. 23andMe has more than 15 million genotyped customers, roughly 80 percent of whom consent to participate in research. 23andMe is able to study the de-identified genetic information of research participants in combination with billions of health data points to identify potential pathways for novel therapeutic targets rooted in human genetic information. Details on the ESMO posters are below. Posters will be available on the 23andMe Therapeutics and Investor websites following the presentations. Abstract: 1069TiPTitle: A Phase 1/2a Dose Escalation and Expansion Study of 23ME-01473, an anti-ULBP6/2/5 Antibody, for Patients with Advanced Solid MalignanciesSession Type: Poster Session – Investigational ImmunotherapyDate and Time: September 14, 9:00-17:00 Central European Summer Time (CEST) Abstract: 620PTitle: Efficacy, safety and PKPD of 23ME-00610, a first-in class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohortSession Type: Poster Session – Developmental TherapeuticsDate and Time: September 14, 9:00-17:00 Central European Summer Time (CEST) Abstract: 153PTitle: 23ME-01473, an Fc-enhanced anti-ULBP6/2/5 antibody, restores anti-tumor NK cell function through NKG2D and FcgRIIIa activation Session Type: Poster Session – Biomarkers and Translational Research (agnostic)Date and Time: September 15, 9:00-17:00 Central European Summer Time (CEST) Abstract: 1706PTitle: Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic clear-cell renal cell carcinoma (ccRCC): Results from a multi-center multi-country Phase 1/2a expansion cohortSession Type: Poster Session – Renal CancerDate and Time: September 15, 9:00-17:00 Central European Summer Time (CEST) Abstract: 150PTitle: Phase 1/2a trial of CD200R1 inhibitor 23ME-00610; exploratory analyses of tissue-based and genetic biomarkersSession Type: Poster Session – Biomarkers and Translational Research (agnostic)Date and Time: September 15, 9:00-17:00 Central European Summer Time (CEST) About 23ME-0061023ME-00610 is a first-in-class anti-CD200R1 monoclonal antibody in the Phase 2a portion of Phase 1/2a clinical development for advanced solid malignancies. CD200R1 was identified as an immuno-oncology (I/O) target from the 23andMe database, with pleiotropic causal variants that have opposing effect on risks for cancer and immune diseases, referred to as an I/O signature, observed in 3 components in this pathway. 23ME-00610 is designed to bind to CD200R1 and prevent the interaction of CD200R1 with CD200. The CD200–CD200R1 axis is an immunological checkpoint that plays a pivotal role in maintenance of immune tolerance. CD200R1 is an inhibitory receptor expressed on T cells and myeloid cells while CD200, the ligand for CD200R1, is highly expressed on certain tumors. In preclinical studies, binding of tumor-associated CD200 to CD200R1 leads to immune suppression and decreased immune cell killing of cancer cells. Preclinical data indicate that this mechanism has the potential to restore the ability for both T-cells and myeloid cells to kill cancer cells. Clinical trials registry (clinicaltrials.gov): NCT05199272. About 23ME-0147323ME-01473 targets ULBP6 to restore anti-tumor immunity through NK and T cells. ULBPs are stress-induced ligands found on the surface of cancer cells that bind to their receptor, NKG2D, on NK and T cells. Cancers escape immune cell recognition by shedding ULBP ligands from their cell surface, which act as immunosuppressive molecular decoys. Blocking the binding of soluble ULBP6 to NKG2D through 23ME-01473 may restore immune cell recognition and killing of cancers. Further, 23ME-01473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells. ULBP6 was identified as a potential cancer drug target using the 23andMe immuno-oncology (I/O) genetic signature, an approach developed by 23andMe to identify evidence for genetic variants that increase immune function while decreasing cancer risk. Using genetic data, 23andMe can identify immune-related genes that are expected to have an impact on cancer biology. Specifically, germline genetics can reveal which of the immune-related genes harbor genetic variants that also alter an individual's predisposition for developing cancer. About 23andMe23andMe is a genetics-led consumer healthcare and biopharmaceutical company empowering a healthier future. For more information, please visit www.23andMe.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise. Contacts:Investor Relations Contact: investors@23andMe.comMedia Contact: press@23andMe.com

免疫疗法ASCO会议临床1期临床结果临床2期

100 项与 23ME-00610 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	23andMe, Inc.	2021-12-29
晚期恶性实体瘤	临床2期	加拿大	23andMe, Inc.	2021-12-29
高肿瘤突变负荷肿瘤	临床2期	美国	23andMe, Inc.	2021-12-29
高肿瘤突变负荷肿瘤	临床2期	加拿大	23andMe, Inc.	2021-12-29
广泛期小细胞肺癌	临床2期	美国	23andMe, Inc.	2021-12-29
广泛期小细胞肺癌	临床2期	加拿大	23andMe, Inc.	2021-12-29
输卵管癌	临床2期	美国	23andMe, Inc.	2021-12-29
输卵管癌	临床2期	加拿大	23andMe, Inc.	2021-12-29
MSI-H 癌症	临床2期	美国	23andMe, Inc.	2021-12-29
MSI-H 癌症	临床2期	加拿大	23andMe, Inc.	2021-12-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05199272 (ESMO2024) 人工标引	临床2期	高肿瘤突变负荷肿瘤 \| MSI-H 癌症 MSI-High \| TMB-High	12	23ME-00610 1400 mg	淵壓顧鑰淵觸憲淵膚窪(願鑰鬱製鬱築構餘網獵) = 壓齋構願繭憲鹽齋獵築鹹衊衊築繭積壓廠鑰選 (鬱艱顧鑰觸觸鏇製鹹餘 ) 更多	积极	2024-09-14
NCT05199272 (23ME-00610, ASCO2024)	临床1/2期	晚期神经内分泌肿瘤 CD200R1 \| CD200 tumor expression \| germline genotyping ... 更多	16	23ME-00610 1400 mg	鬱壓蓋夢齋夢蓋獵網襯(範觸壓醖鑰鏇餘繭鹹構) = 12.5% vs 0% 艱繭餘鹹鹽醖淵齋範齋 (繭積鹽糧壓範壓壓糧鹽 ) 更多	积极	2024-05-24
GlobeNewswire 人工标引	临床1/2期	晚期恶性实体瘤	28	23ME-00610	(獵鑰齋簾襯鑰鏇構遞繭) = One treatment-related AE (600 mg dose) leading to discontinuation was observed: a non-serious grade 3 adverse event, maculopapular rash in Cycle 1, 積膚鑰範壓簾築繭膚網 (淵鑰艱淵獵觸顧鏇選廠 ) 更多	积极	2023-11-06
NCT05199272 (609, SITC2023)	临床1/2期	晚期恶性实体瘤 CD200R1	-	23ME-00610 2mg	醖鹽糧鬱獵醖遞獵獵鹽(鹽鑰膚選鹽簾觸壓繭積) = 鬱廠繭鹽醖遞壓醖範觸構顧鏇齋齋製廠窪繭襯 (鬱網齋壓鑰繭膚窪鏇襯 ) 更多	积极	2023-11-02
NCT05199272 (609, SITC2023)	临床1/2期	晚期恶性实体瘤 CD200R1	-	23ME-00610 60mg	醖鹽糧鬱獵醖遞獵獵鹽(鹽鑰膚選鹽簾觸壓繭積) = 製觸鏇艱築齋艱網獵衊構顧鏇齋齋製廠窪繭襯 (鬱網齋壓鑰繭膚窪鏇襯 ) 更多	积极	2023-11-02
NCT05199272 (AACR2023) 人工标引	临床1/2期	晚期恶性实体瘤	21	23ME-00610	襯艱艱廠鏇鑰遞艱範獵(窪艱積願鹹壓鏇艱鬱窪) = 夢鹹膚網繭獵鏇艱繭簾鹽繭齋範築築醖壓獵餘 (夢餘鬱製壓窪夢膚醖憲 )	积极	2023-04-14
NCT05199272 (AACR2023) 人工标引	临床1/2期	晚期恶性实体瘤	21	23ME-00610	壓網遞網製窪窪鹹鏇選(淵窪壓艱鬱窪艱製廠艱) = 積獵鑰醖願鑰齋獵鑰淵獵鹹築網築艱餘餘鬱壓 (顧顧膚製鑰蓋簾積網築 )	积极	2023-04-14